Gastrointestinal Cancer Clinical Trial
Official title:
A Phase I/II Study of RAD001 and AV-951 in Patients With Refractory, Metastatic Colorectal Cancer
Research has shown that anti-angiogenic agents can be effective therapies to treat cancer. Anti-angiogenic agents target the blood vessels required for tumors to grow. Vascular endothelial growth factor (VEGF) is one of the cell pathways used for this blood vessel growth. When the investigators interfere with the VEGF pathway, the investigators inhibit this blood vessel growth which is required by tumors. One of the study drugs being used, tivozanib (AV-951), selectively interferes with the VEGF pathway. The second study drug being used, everolimus (RAD001) interferes with the mTOR pathway. The mTOR pathway is another pathway involved in blood vessel and tumor cell growth. By combining these two drugs the investigators hope to slow or reverse tumor cell growth in patients whose tumors have become resistant to other therapies for their disease.
Primary Objective
Phase I
- To determine the safety, tolerability, and maximally tolerated dose (MTD) of everolimus
and tivozanib administered in combination to patients with advanced gastrointestinal
tumors.
Phase II
- At the MTD, to assess progression-free survival associated with everolimus and
tivozanib in patients with refractory, metastatic colorectal cancer.
Secondary Objectives
Phase II
- To assess tumor response rate.
- To assess overall survival.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Not yet recruiting |
NCT05044312 -
Sleep Disturbances in Surgical Patients With GI Cancers: A Quantitative and Qualitative Analysis
|
N/A | |
| Active, not recruiting |
NCT05053191 -
Advancing Nursing Practices in Hospital Oncology Care
|
N/A | |
| Completed |
NCT03611309 -
Perioperative Palliative Care Surrounding Cancer Surgery for Patients & Their Family Members
|
N/A | |
| Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
| Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06398314 -
Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors
|
N/A | |
| Withdrawn |
NCT04030624 -
Remote Electronic Patient Monitoring in Gastrointestinal Cancer
|
N/A | |
| Completed |
NCT02222259 -
A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients
|
N/A | |
| Completed |
NCT02140593 -
The Laparotomy Study
|
Phase 4 | |
| Active, not recruiting |
NCT00716209 -
Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers
|
N/A | |
| Recruiting |
NCT01484444 -
Biomarker Analysis of Gastrointestinal Cancer
|
N/A | |
| Completed |
NCT02130427 -
A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy
|
N/A | |
| Active, not recruiting |
NCT00710632 -
Screening to Predict Weight Loss in Patients With Cancer
|
N/A | |
| Completed |
NCT00094965 -
Oxaliplatin With FOLFOX4 in Patients With Normal and Abnormal Renal Function
|
Phase 2 | |
| Terminated |
NCT04077372 -
Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal Cancers
|
N/A | |
| Recruiting |
NCT04899908 -
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
|
Phase 2 | |
| Recruiting |
NCT05429866 -
Immunological Variables Associated to ICI Toxicity in Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT05226221 -
Gastrointestinal Emergency Surgery: Evaluation of Morbidity and Mortality
|
||
| Recruiting |
NCT03286348 -
Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer
|
N/A |